Small Molecule Therapeutics Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer

@inproceedings{Hunter2014SmallMT,
  title={Small Molecule Therapeutics Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer},
  author={Francis W. Hunter and Huai-Ling Hsu and Jiechuang Su and Susan M. Pullen and William R. Wilson and Jingli Wang},
  year={2014}
}
Triple-negative breast cancer (TNBC) is an aggressive malignancy with poor clinical outcome and few validated drug targets. Two prevalent features of TNBC, tumor hypoxia and derangement of homologous recombination (HR) repair, are potentially exploitable for therapy. This study investigated whether hypoxia-activated prodrugs (HAP) of DNA-damaging cytotoxins may inhibit growth of TNBC by simultaneously addressing these two targets. We measured in vitro activity of HAP of DNA breakers… CONTINUE READING